Natrecor Recommended Use Initiative Differs Slightly From Panel Advice
Executive Summary
Scios' new educational materials for Natrecor (nesiritide) will recommend use of the drug for hospitalized patients with either dyspnea at rest or minimal activity - a slight departure from advice offered by a panel of experts recently convened by the Johnson & Johnson subsidiary
You may also be interested in...
Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics
Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics
J&J Natrecor “Dear Doctor” Letter Advises Against Outpatient Use
Administration of Johnson & Johnson/Scios' Natrecor (nesiritide) in the outpatient setting is an "unsupported use" of the congestive heart failure therapy, the company said in a letter to health care practitioners